Seeing Is Believing
Currently out of the existing stock ratings of Josh Schimmer, 133 are a BUY (87.5%), 17 are a HOLD (11.18%), 2 are a SELL (1.32%).
Analyst Josh Schimmer, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 53.17% that have a potential upside of 49.75% achieved within 305 days.
Josh Schimmer’s has documented 635 price targets and ratings displayed on 33 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on BBIO, BridgeBio Pharma at 21-Feb-2025.
Analyst best performing recommendations are on SPRO (SPERO THERAPEUTICS).
The best stock recommendation documented was for SPRO (SPERO THERAPEUTICS) at 5/4/2022. The price target of $2 was fulfilled within 2 days with a profit of $0.25 (14.29%) receiving and performance score of 71.43.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$205
$22.5 (12.33%)
3 years 9 months 17 days ago
(05-May-2021)
3/5 (60%)
$35.09 (20.65%)
938
Hold
$173
$-9.5 (-5.21%)
$156
3 years 9 months 19 days ago
(03-May-2021)
14/24 (58.33%)
$2.73 (1.60%)
682
Hold
$190
3 years 9 months 27 days ago
(26-Apr-2021)
9/11 (81.82%)
$34.41 (22.12%)
350
Hold
$166
$-16.5 (-9.04%)
$175
4 years 18 days ago
(04-Feb-2021)
23/23 (100%)
$10.41 (6.69%)
828
Buy
$155
4 years 1 months 15 days ago
(07-Jan-2021)
7/7 (100%)
$36.79 (31.12%)
395
Which stock is Josh Schimmer is most bullish on?
Which stock is Josh Schimmer is most reserved on?
What Year was the first public recommendation made by Josh Schimmer?